Skip to content

ND0612 clinical trials current status:

Phase 1

NeuroDerm has completed 8 Phase-I and clinical pharmacology studies, ranging from small dose-finding studies to 12-month population pharmacokinetics studies. These studies support the conclusions that ND0612 provides stable and continuous delivery of levodopa and carbidopa at clinically meaningful levels.

Let's stay in touch

For general inquiries or to learn more about NeuroDerm, please complete the form below. For medical information or to report on your own health or experience, please consult your healthcare provider. Please click here for information about our clinical trials.

*
*
*
*